Guidelines
30 September 2025
Vol. 3 No. 3 (2025)
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025 - Focus on prevention and treatment of cardiometabolic disease
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Disclaimer
Disclaimer: The Global Implementation Guidelines (the “Documents”) represent the views of its authors. They were produced after careful consideration of the scientific and medical knowledge and the evidence and related economic issues that may impact implementation of therapies, as well as the main guidelines on the topic, available at the time of their publication. The iCARDIO Alliance, respectively its Partner Organizations and the TMA, are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the Documents and any other official recommendations or guidelines issued by other bodies in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the Documents fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. On the other hand, the Documents do not override the individual responsibility of health professionals to make the appropriate, accurate and individual decisions in consideration of each patient’s health condition. These decisions should be taken in consultation with their individual patient and, where appropriate and/or necessary, the patient’s caregiver. The Documents do not exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines, issued by the competent public health authorities that govern them. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
Disclaimer: The Global Implementation Guidelines (the “Documents”) represent the views of its authors. They were produced after careful consideration of the scientific and medical knowledge and the evidence and related economic issues that may impact implementation of therapies, as well as the main guidelines on the topic, available at the time of their publication. The iCARDIO Alliance, respectively its Partner Organizations and the TMA, are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the Documents and any other official recommendations or guidelines issued by other bodies in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the Documents fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. On the other hand, the Documents do not override the individual responsibility of health professionals to make the appropriate, accurate and individual decisions in consideration of each patient’s health condition. These decisions should be taken in consultation with their individual patient and, where appropriate and/or necessary, the patient’s caregiver. The Documents do not exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines, issued by the competent public health authorities that govern them. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
3033
Views
3840
Downloads
Authors
There are a number of guidelines on how to manage obesity, but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our Global Guidelines emphasize the incorporation of novel therapies, while integrating standards of care with the most up-to-date evidence to enable clinicians to optimize obesity management. Context-specific recommendations tailored to individual patient needs are highlighted, providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that improves patient outcomes and reduces the burden of hospitalization in this susceptible population. These Global Guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guidelines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged, and – most importantly – also provide recommendations on several issues where resource limitations may put constraints on the care provided to patients living with obesity. Such “economic adjustment” recommendations aim to guide situations when “Resources are somewhat limited” or when “Resources are severely limited”. Hence, this document presents a comprehensive update to obesity management guidelines, thereby aiming to provide a unified strategy for the pharmacological, non-pharmacological, and invasive management of this significant global health challenge that is applicable to the needs of healthcare around the globe.
Altmetrics
Downloads
Download data is not yet available.
Citations
1. WHO Expert Consultation. Appropriate bodymass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:15763.
2. Rodgers A, Woodward A, Swinburn B, et al. Prevalence trends tell us what did not precipitate the US obesity epidemic. Lancet Public Health 2018;3:e162e163.
3. Temple NJ. The origins of the obesity epidemic in the USA. Lessons for today. Nutrients. 2022;14:4253.
4. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025;13:22162.
5. Golubnitschaja O, Liskova A, Koklesova L, et al. Caution, «normal» BMI: health risks associated with potentially masked individual underweight. EPMA Position Paper 2021. EPMA J 2021;12:24364.
6. Ng M, Gakidou E, Lo J, et al. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 2025;405:81338.
7. Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm 2021;27:35466.
8. Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obes Rev 2011;12:5061.
9. Okunogbe A, Nugent R, Spencer G, et al. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Global Health 2022;7:e009773.
10. No authors listed. Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—The evidence report. National Institutes of Health. Obes Res 1998;6:51s209s. Erratum in Obes Res 1998;6:464.
11. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016;22:S1203.
12. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 2023;44:404340.
13. Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology 2022;163:119825.
14. Nutrition and Metabolic Management Branch of China International Exchange and Promotive Association for Medical and Health Care, Clinical Nutrition Branch of Chinese Nutrition Society, Chinese Diabetes Society, et al. Guidelines for medical nutrition treatment of overweight/obesity in China (2021). Asia Pac J Clin Nutr 2022;31:45082.
15. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes 2024. Diabetes Care 2024;47:S15878.
16. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227337.
17. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2019;140:e596e646.
18. Jain R, Stone JA, Agarwal G, et al. Canadian Cardiovascular Harmonized National Guideline Endeavour (CCHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update. CMAJ 2022;194:E146080.
19. Nelson MR, Banks E, Brown A, et al. 2023 Australian guideline for assessing and managing cardiovascular disease risk. Med J Aust 2024;220:48290.
20. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105:s117s314.
21. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension 2018;71:e13e115.
22. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023;41:18742071.
23. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: CoSponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28:52862.
24. Handelsman Y, Anderson JE, Bakris GL, et al. DCRM: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications 2022;36:108101.
25. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599726.
26. Atherton JJ, Sindone A, De Pasquale CG, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung Circ 2018;27:1123208.
27. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ 2020;192:E875.
28. Gilbert O, Gulati M, Gluckman TJ, et al. 2025 concise clinical guidance: An ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2025;86:53655.
29. Wang T, Tan JY, Liu XL, et al. Barriers and enablers to implementing clinical practice guidelines in primary care: an overview of systematic reviews. BMJ Open 2023;13:e062158.
30. Żukiewicz-Sobczak W, Wróblewska P, Zwoliński J, et al. Obesity and poverty paradox in developed countries. Ann Agric Environ Med 2014;21:5904.
31. Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation 2023;148:163664.
32. U.S. Food and Drug Administration. FDA Approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
33. Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes Endocrinol 2021;9:41926.
34. Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med 2020;26:48597.
35. O’Brien KS, Latner JD, Puhl RM, et al. The relationship between weight stigma and eating behavior is explained by weight bias internalization and psychological distress. Appetite 2016;102:706.
36. Vartanian LR, Porter AM. Weight stigma and eating behavior: A review of the literature. Appetite 2016;102:314.
37. Vallis M, Piccinini Vallis H, Sharma AM, et al. Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care. Can Fam Physician 2013;59:2731.
38. Romero-Corral A, Somers VK, Sierra Johnson J, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (London) 2008;32:95966.
39. Wang J, Thornton JC, Russell M, et al. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. Am J Clin Nutr 1994;60:238.
40. World Health Organization. Waist circumference and waist–hip ratio: report of a WHO expert consultation. Available from: https://www.who.int/publications/i/item/9789241501491
41. Muñoz-Hernando J, Luque V, Ferré N, et al. Diagnosis accuracy of waist-to-height ratio to predict cardiometabolic risk in children with obesity. Pediatr Res 2023;93:1294301.
42. Parikh RM, Joshi SR, Pandia K. Index of central obesity is better than waist circumference in defining metabolic syndrome. Metab Syndr Relat Disord 2009;7:5258.
43. Deurenberg P, DeurenbergYap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 2002;3:1416.
44. Karter AJ, Schillinger D, Adams AS, et al. Elevated rates of diabetes in Pacific Islanders and Asian subgroups: The Diabetes Study of Northern California (DISTANCE). Diabetes Care 2013;36:5749.
45. Samouda H, Langlet J. Body fat assessment in youth with overweight or obesity by an automated bioelectrical impedance analysis device, in comparison with the dual-energy x-ray absorptiometry: a cross sectional study. BMC Endocr Disord 2022;22:195.
46. Deurenberg P. Limitations of the bioelectrical impedance method for the assessment of body fat in severe obesity. Am J Clin Nutr 1996;64:449S52S.
47. Ginde SR, Geliebter A, Rubiano F, et al. Air displacement plethysmography: validation in overweight and obese subjects. Obes Res 2005;13:12327.
48. Wilson K. Obesity: lifestyle modification and behavior interventions. FP Essent 2020;492:1924.
49. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the management of overweight and obesity in adults. Circulation 2014;129:S10238.
50. Esposito K, Kastorini CM, Panagiotakos DB, et al. Mediterranean diet and weight loss: metaanalysis of randomized controlled trials. Metab Syndr Relat Disord 2011;9:112.
51. Poulimeneas D, Anastasiou CA, Santos I, et al. Exploring the relationship between the Mediterranean diet and weight loss maintenance: the MedWeight study. Br J Nutr 2020;124:87480.
52. Soltani S, Shirani F, Chitsazi MJ, et al. The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults: a systematic review and meta-analysis of randomized controlled clinical trials. Obes Rev 2016;17:44254.
53. Almabruk BA, Alharbi SH, Alsaqer FS, et al. The role of intermittent fasting on metabolic syndrome: a systematic review and metaanalysis. Cureus 2024;16:e71623.
54. Santesso N, Akl EA, Bianchi M, et al. Effects of higher- versus lower-protein diets on health outcomes: a systematic review and meta-analysis. Eur J Clin Nutr 2012;66:7808.
55. Astrup A, Grunwald GK, Melanson EL, et al. The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes Relat Metab Disord 2000;24:154552.
56. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008:359:22941.
57. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extravirgin olive oil or nuts. N Engl J Med 2018;378:e34.
58. Noto H, Goto A, Tsujimoto T, et al. Low-carbohydrate diets and all-cause mortality: a systematic review and meta-analysis of observational studies. PLoS One 2013;8:e55030.
59. Sun J, Ruan Y, Xu N, et al. The effect of dietary carbohydrate and calorie restriction on weight and metabolic health in overweight/obese individuals: a multicenter randomized controlled trial. BMC Med 2023;21:192.
60. Wycherley TP, Moran LJ, Clifton PM, et al. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2012;96:128198.
61. Bellicha A, van Baak MA, Battista F, et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies. Obes Rev 2021;22:e13256.
62. Weiss EP, Jordan RC, Frese EM, et al. Effects of weight loss on lean mass, strength, bone, and aerobic capacity. Med Sci Sports Exerc 2017;49:20617.
63. Ohkawara K, Tanaka S, Miyachi M, et al. A dose-response relation between aerobic exercise and visceral fat reduction: systematic review of clinical trials. Int J Obes (Lond) 2007;31:178697.
64. Swift DL, McGee JE, Earnest CP, et al. The effects of exercise and physical activity on weight loss and maintenance. progress in cardiovascular diseases. Prog Cardiovasc Dis 2018;61:20613.
65. Willis LH, Slentz CA, Bateman LA, et al. Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol (1985) 2012;113:18317.
66. Catenacci VA, Ogden LG, Stuht J, et al. Physical activity patterns in the National Weight Control Registry. Obesity (Silver Spring) 2008;16:15361.
67. Jakicic JM, Marcus BH, Lang W, et al. Effect of exercise on 24-month weight loss maintenance in overweight women. Arch Intern Med 2008;168:15509.
68. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:31122.
69. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:1122.
70. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond) 2013;37:144351.
71. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA 2015;314:68799.
72. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 2016;40:13109.
73. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:242434.
74. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight managementin individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389:13991409.
75. Hinnen D. Glucagonlike peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr 2017;30:20210.
76. Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med 2023;33:15966.
77. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:9891002.
78. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:97184.
79. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325:140313.
80. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA 2021;325:141425.
81. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:208391.
82. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022;327:13850.
83. Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med 2024;391:157383.
84. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025. Online ahead of print.
85. Lingvay I, Bergenheim SJ, Buse JB, et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025. Online ahead of print.
86. Sattar N, Frühbeck G, Andreelli F, et al. Weight reduction with tirzepatide varied meaningfully by baseline HbA1c category in adults with overweight or obesity and type 2 diabetes in SURMOUNT2. Diabetes Care 2025. Online ahead of print.
87. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:61326.
88. Lincoff AM, BrownFrandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:222132.
89. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:106984.
90. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394407.
91. Haykowsky MJ, Brubaker PH, John JM, et al. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol 2011;58:26574.
92. Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 2025;405:158093.
93. Sanyal Arun J, Newsome Philip N, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis. N Engl J Med 2025;392:208999.
94. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:14355.
95. Frías Juan P, Davies Melanie J, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:50315.
96. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as addon to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021;398:58398.
97. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:181124.
98. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS5 randomized clinical trial. JAMA 2022;327:53445.
99. Jastreboff Ania M, Aronne Louis J, Ahmad Nadia N, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:20516.
100. Jastreboff AM, Roux CWl, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2025;392:95871.
101. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT3 phase 3 trial. Nat Med 2023;29:290918.
102. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT4 randomized clinical trial. JAMA 2024;331:3848.
103. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:2636.
104. Malhotra A, Grunstein Ronald R, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391:1193205.
105. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024;391:299310.
106. Packer M, Zile Michael R, Kramer Christopher M, et al. Tirzepatide for Heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:42737.
107. Lilly Investors [Internet]. Lilly’s Mounjaro (tirzepatide), a GIP/GLP1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. Accessed: 22 Sept, 2025 Available from: https://investor.lilly.com/newsreleases/newsreleasedetails/lillysmounjarotirzepatidegipglp1dualagonistdemonstrated
108. Usman MS, Bhatt DL, Hameed I, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2024;12:44761.
109. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998;16:20137.
110. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:16772.
111. Zahmatkesh A, Sohouli MH, Shojaie S, et al. The effect of orlistat in the treatment of nonalcoholic fatty liver in adolescents with overweight and obese. Eur J Pediatr 2024;183:117382.
112. Alanazi J, Unnisa A, Ahmad S, et al. Significance of orlistat in management of dyslipidemia, systolic blood pressure and body mass index. Eur Rev Med Pharmacol Sci 2022;26:832632.
113. Cignarella A, Busetto L, Vettor R. Pharmacotherapy of obesity: An update. Pharmacol Res 2021;169:105649.
114. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:33042.
115. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss. Pharmacol Res 2014;84:111.
116. Tek C. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives. Patient Prefer Adherence 2016;10:7519.
117. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (CORI): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595605.
118. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (CORII). Obesity (Silver Spring) 2013;21:93543.
119. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36:
40229.
120. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the CORBMOD trial. Obesity (Silver Spring) 2011;19:11020.
121. Gazewood JD, Barry K. Phentermine/topiramate (Qsymia) for chronic weight management. AAFP. 2024. Available from: https://www.aafp.org/pubs/afp/issues/2014/1015/p576.html
122. Garvey WT, Blüher M, Osorto Contreras Cynthia K, et al. Co-administered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med 2025;393:63547.
123. Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP1 receptor agonist, in early type 2 diabetes. N Engl J Med 2025;393:106576.
124. Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol 2018;14:1224.
125. Kremen AJ, Linner JH, Nelson CH. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Ann Surg 1954;140:43948.
126. Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in nonalcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023;401:178697.
127. Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med 377:114355.
128. le Roux CW, Bloom SR. Why do patients lose weight after Roux-en-Y gastric bypass? J Clin Endocrinol Metab 2005;90:5912.
129. Abdeen G, le Roux CW. Mechanism underlying the weight loss and complications of Roux-en-Y gastric bypass. Review. Obes Surg 2016;26:41021.
130. Biter LU, ‘t Hart JWH, Noordman BJ, et al. Long-term effect of sleeve gastrectomy vs Roux-en-Y gastric bypass in people living with severe obesity: a phase III multicentre randomised controlled trial (SleeveBypass). Lancet Reg Health Eur 2024;38:100836.
131. Hedberg S, Thorell A, Österberg J, et al. Comparison of sleeve gastrectomy vs Roux-en-Y gastric bypass: a randomized clinical trial. JAMA Netw Open 2024;7:e2353141.
132. Abu Dayyeh BK, Maselli DB, Rapaka B, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomized clinical trial. Lancet 2021;398:196573.
133. Angrisani L, Cutolo PP, Formisano G, et al. Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 10-year results of a prospective, randomized trial. Surg Obes Relat Dis 2013;9:40513.
134. Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg 1998;22:93646.
135. Sorribas M, Casajoana A, Sobrino L, et al. Experience in biliopancreatic diversion with duodenal switch: Results at 2, 5 and 10 years. Cir Esp (Engl Ed) 2022;100:2028.
136. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:172437.
137. US Preventive Services Task Force, Grossman 1DC, Bibbins-Domingo K, et al. Screening for obesity in children and adolescents: US preventive services task force recommendation statement. JAMA 2017;317:241726.
138. National Institute for Health and Care Excellence. Overweight and obesity management. 2025. Available from: https://www.nice.org.uk/guidance/ng246
139. Fox CK, Barrientos-Pérez M, Bomberg EM, et al. Liraglutide for children 6 to <12 years of age with obesityA randomized trial. N Engl J Med 2025;392:55565.
140. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med 2022;387:224557.
141. Kelly Aaron S, Auerbach P, Barrientos-Pérez M, et al. A Randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med 2020;382:211728.
142. No authors listed. Physical activity and exercise during pregnancy and the postpartum period: ACOG Committee Opinion Summary, Number 804. Obstet Gynecol 2020;135:e17888.
143. Laufer J, Scasso S, Bentancor V, et al. Autologous transobturator sling as an alternative therapy for stress urinary incontinence. Int J of Gynaecol Obstet 2019;145:3005.
144. Denison FC, Aedla NR, Keag O, et al. Care of women with obesity in pregnancy: green-top guideline No. 72. BJOG 2019;126:e62e106.
145. Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines. Weight Gain during pregnancy: reexamining the guidelines. Washington (DC), National Academies Press (US); 2009.
146. National Institute for Health and Care Excellence. PH27: Weight management before, during and after pregnancy 2010. Available from: https://www.nice.org.uk/guidance/ph27
147. Laskov I, Kessous R, Abitbol J, et al. Risk of thromboembolic disease with cost estimates in patients undergoing robotic assisted surgery for endometrial cancer and review of the literature. J Obstet Gynaecol Can 2018;40:15719.
148. American Diabetes Association Professional Practice Committee. Diabetes Care in the hospital: standards of care in diabetes 2024. Diabetes Care 2023;47:S295S306.
149. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract 2008;14:183.
150. An R, Shen J, Xiao Y. Applications of artificial intelligence to obesity research: scoping review of methodologies. J Med Internet Res 2022;24:e40589.
151. Du J, Yang S, Zeng Y, et al. Visualization obesity risk prediction system based on machine learning. Sci Rep 2024;14:22424.
153. Pedersen SD, Manjoo P, Dash S, et al.. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ 2025;197:E797E809.
153. Pinto FJ, Anker SD, Abraham WT, et al. The Global Implementation Guidelines Initiative: how to optimize cardiorenalmetabolic care worldwide. Global Cardiology 2025;3:68.
How to Cite
1.
Anker SD, Ji L, Kindel T, Coats AJ, Ojji D, Puente Barragán A, et al. iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025 - Focus on prevention and treatment of cardiometabolic disease. Global Cardiol [Internet]. 2025 Sep. 30 [cited 2026 May 25];3(3). Available from: https://www.globalcardiology.info/site/article/view/86
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
